Skip to main content
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TVRD ISIN · US1407553072 LEI · 549300COVOY41P0GZ881 IL Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2025-02-13 Regulatory Filings
Country US United States of America
Listing IL TVRD

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a response letter from Cara Therapeutics, Inc. to the SEC staff regarding comments on an Amendment No. 1 to a Registration Statement on Form S-4. The Form S-4 is a filing used for mergers and acquisitions, specifically for registration of securities in connection with business combinations. The letter discusses revisions to disclosures in the Second Amended Registration Statement, financial forecasts, fairness opinions, and other merger-related details. There is no actual financial report or earnings data presented; rather, this is a regulatory correspondence addressing SEC comments on a merger registration statement. Therefore, this document is best classified under Regulatory Filings (RNS) as it is a regulatory response letter and does not itself constitute the merger filing or a financial report.
2025-02-13 English
Regulatory Filings 2025
Regulatory Filings
2025-02-12 English
Director's Dealing 2025
Director's Dealing
2025-02-07 English
FORM S-4/A
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It contains detailed information about a proposed merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc., including terms of the merger, stock issuance, voting proposals, and other transaction-related details. The presence of merger agreement details, stockholder meeting proposals related to the merger, and the registration of securities for the merger clearly indicate this is related to M&A activity. The document is not a proxy statement alone, nor is it a simple announcement or a report like an annual or quarterly report. It is a comprehensive filing related to a merger transaction. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length (15,000 characters) and content confirm it is a full filing, not just an announcement or summary.
2025-01-27 English
Merger & Acquisition 2025
Merger & Acquisition Classification · 95% confidence The document is a detailed response letter from a company and its legal counsel to the SEC staff comments regarding a Registration Statement on Form S-4. The text references amendments to the Registration Statement, proxy statement/prospectus disclosures, merger details, voting proposals, financial forecasts, and Nasdaq compliance issues. The Form S-4 is a registration statement used for mergers and acquisitions involving securities. The content focuses on merger-related disclosures, financial advisor opinions, voting requirements, and regulatory compliance related to the merger transaction. This is consistent with filings related to merger and acquisition activities rather than annual reports, earnings releases, or other categories. Therefore, the document is best classified under Merger & Acquisition (MA) filings, which include merger communications and related SEC filings such as Form S-4 and amendments thereto.
2025-01-25 English
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cara Therapeutics, Inc. dated January 16, 2025. It discloses a merger agreement with Tvardi Therapeutics, Inc. and includes an investor presentation as an exhibit. The text references the merger transaction, proxy solicitation materials, and forward-looking statements typical of merger-related filings. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is primarily an announcement and disclosure related to a merger transaction and includes an investor presentation. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). Therefore, this document should be classified as M&A Activity.
2025-01-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.